Market Access NICE to consult on inflation-busting fee increases NICE ran a webinar on 2nd November, setting out – ahead of a formal consultation due to open on 21s
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face